According to a review of research, a new diabetes medication called Tirzepatide, marketed as Mounjaro by Eli Lilly, has been found to result in greater weight loss and lower blood sugar levels compared to its rival drug Semaglutide (also known as Ozempic). Currently approved for treating type 2 diabetes in the US, Europe, and the UK, Eli Lilly is seeking authorization to use Tirzepatide for obesity treatment in the US, which would put it in direct competition with Novo Nordisk's Semaglutide, known as Ozempic for diabetes and Wegovy for weight loss.
The study, conducted by Greek researchers, analyzed data from 22 previous randomized control trials involving nearly 18,500 patients with type 2 diabetes. The researchers compared the effects of different doses of Tirzepatide and Semaglutide over a minimum of 12 weeks. The highest dose of Tirzepatide resulted in an average weight loss of 5.7 kilograms (12.5 pounds) more than Semaglutide and a two percent reduction in blood sugar levels compared to the highest dose of Semaglutide. However, the highest dose of Tirzepatide was associated with increased gastrointestinal side effects.
It is important to note that the research has not undergone peer review and will be presented at an upcoming diabetes conference in Germany. Experts caution that the study should have directly compared the two drugs and emphasize the need to prioritize access to these medications for individuals with type 2 diabetes who have the greatest need. Previous studies have shown that the highest dose of Tirzepatide can lead to an average weight loss of 15 percent over 72 weeks, but the weight may return if the drug is discontinued. Both Tirzepatide and Semaglutide mimic the hormone GLP-1, which regulates appetite, but Tirzepatide additionally targets the hormone GIP, which stimulates insulin release. Sales of Mounjaro reached nearly $1 billion in the second quarter of this year alone.
Kindly comment and share this article
No comments:
Post a Comment